FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For November 2002
AstraZeneca PLC
15 Stanhope Gate, London W1K 1LN, England
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F
--- ---
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
Yes No X
--- ---
If "Yes" is marked, indicate below the file number assigned to the Registrant
in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
Item
-----
1. Press release entitled, "Omeprazole Patent Litigation -
AstraZeneca to appeal US Court's Judgment relating to KUDCo and
Schwarz Pharma", dated 5 November 2002.
2. Press release entitled "AstraZeneca's New Statin, Crestor,
Receives First Approval in Europe" dated 7 November 2002.
3. Press release entitled "AstraZeneca Reports Significant Progress
Across Its Promising Research and Development Portfolio" dated 7
November 2002.
4. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 11 November 2002.
5. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 13 November 2002.
6. Press release entitled "AstraZeneca PLC - Directorate
Announcement" dated 14 November 2002
7. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 14 November 2002.
8. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 15 November 2002.
9. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 18 November 2002.
10. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 21 November 2002.
11. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 22 November 2002.
12. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 25 November 2002.
13. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 26 November 2002.
14. Press release entitled "Dealing by Directors" dated 26 November
2002.
15. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 27 November 2002.
16. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 28 November 2002.
17. Press release entitled "Repurchase of Shares in AstraZeneca PLC"
dated 29 November 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AstraZeneca PLC
Date: 1 December 2002 By: /s/ G H R Musker
--------------------------------
Name: G H R Musker
Title: Company Secretary & Solicitor
Item 1
OMEPRAZOLE PATENT LITIGATION - ASTRAZENECA TO APPEAL US COURT'S JUDGMENT
RELATING TO KUDCo AND SCHWARZ PHARMA
AstraZeneca's initial detailed review of the Court's 11th October 2002 opinion
relating to KUDCo and Schwarz Pharma has revealed that the United States
District Court, Southern District of New York, made reversible errors in
determining key facts and applying the law. AstraZeneca has therefore decided
to appeal the portions of the Court's judgment relating to KUDCo and Schwarz
Pharma.
5 November 2002
Media Enquiries:
Steve Brown, Tel: +44 (0)207 304 5033
Chris Major, Tel: +44 (0)207 304 5028
Emily Denney, Tel: +44 (0)207 304 5034
Rachel Bloom-Baglin, Tel: +1 302 886 7858
Investor Relations:
Mina Blair-Robinson, Tel: +44 (0)207 304 5084
Jonathan Hunt, Tel: +44 (0)207 304 5087
-Ends-
Item 2
ASTRAZENECA'S NEW STATIN, CRESTOR(TM), RECEIVES FIRST APPROVAL IN EUROPE
Other European markets should follow in 2003
AstraZeneca announced today it has received the first approval for CRESTOR(TM)
(rosuvastatin) 10-40 mg from the Medicines Evaluation Board (MEB) in the
Netherlands for the management of primary hypercholesterolaemia and mixed
dyslipidaemia.
Sir Tom McKillop, Chief Executive of AstraZeneca, said, "We are delighted to
have received this first approval of CRESTOR, which represents another
milestone for the company. CRESTOR is an outstanding product that will enable
more patients across the world to reach their target LDL cholesterol levels,
and aid in the global fight against coronary heart disease."
The Netherlands MEB will act as the Reference Member State for the European
Mutual Recognition Procedure leading to further approvals in 16 other countries
in Europe--beginning in the first half of 2003. CRESTOR is also awaiting
approval in the USA, Japan and in other markets.
The clinical development programme for CRESTOR now involves over 15,000
patients and includes a number of head-to-head comparative studies. In multiple
clinical studies, CRESTOR has been shown to be more effective in lowering
LDL-cholesterol (LDL-C or 'bad' cholesterol) than the currently prescribed
statins. It has demonstrated reductions of 52% to 63% across the dose range,
and compared to the same doses of atorvastatin, CRESTOR provided a significant
8.4% greater reduction in LDL-C. CRESTOR 10mg gets significantly more patients
to their European LDL-C goal than atorvastatin 10mg (82% v 51% respectively),
simvastatin 20mg (80% v 48%) and pravastatin 20mg (80% v 16%). In addition to
the dramatic reductions seen in LDL-C, CRESTOR
2
produces a significant increase in HDL-C ('good' cholesterol), as well as
reducing total cholesterol and triglycerides.
The excellent efficacy of CRESTOR, together with a safety profile, which the
company believes is comparable to the marketed statins, will position CRESTOR
as a highly effective competitor in the global statin market, estimated to be
worth more than $18 billion and growing at a rate of about 20 per cent
annually.
Dr Hamish Cameron, Vice President and Head of Cardiovascular Therapy Area at
AstraZeneca, said, "Despite many medical advances, hypercholesterolaemia
remains poorly controlled. Approximately half of the people on cholesterol
lowering therapy are still not reaching their cholesterol targets and are at
risk of heart attacks and strokes. With the efficacy we've seen in clinical
studies, CRESTOR could make a real difference to these patients' lives."
A copy of the English version of the approved label for CRESTOR(TM) in The
Netherlands (rosuvastatin) can be found at
www.astrazeneca.com/redirector/index.asp?id=6
Details on the approval of CRESTOR(TM) (rosuvastatin) will be provided by Dr
Hamish Cameron at 08.30 GMT today as a part of the company's Annual Business
Review. Dial in details for this event can be found at
www.astrazeneca.com/redirector/index.asp?id=5
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of ethical (prescription)
pharmaceuticals and the supply of healthcare services. It is one of the top
five pharmaceutical companies in the world with healthcare sales of over $16.4
billion and leading positions in sales of gastrointestinal, oncology,
anaesthesia including pain management, cardiovascular, central nervous system
(CNS) and respiratory products. AstraZeneca has more than 40 years experience
in cardiovascular medicine and aims to increase lifespan and improve quality of
life by reducing the
3
risk, prevalence and impact of cardiovascular disease. AstraZeneca has a
comprehensive cardiovascular portfolio including CRESTOR, ATACAND, ZESTRIL,
TENORMIN, SELOKEN ZOK/TOPROL XL AND PLENDIL. This heritage is complemented by
an innovative pipeline including the first oral direct thrombin inhibitor,
EXANTA, and a novel treatment for type 2 diabetes / metabolic syndrome, GALIDA.
7 November 2002
Media Enquiries:
Steve Brown, Tel: +44 (0) 207 304 5033
Emily Denney, Tel: +44 (0) 207 304 5034
Investor Relations:
Mina Blair-Robinson, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Notes to editors:
Coronary heart disease (CHD) is a major cause of morbidity and the leading
cause of death in the Western world. LDL-C is the most significant contributory
risk factor to atherosclerosis, a common cause of CHD and elevated levels of
cholesterol is one of the most important risk factors in predicting CHD risk in
the population.
AstraZeneca licensed worldwide rights to CRESTOR from Shionogi & Co Ltd, Osaka,
Japan, the company that discovered the drug, in April 1998. AstraZeneca carried
out a comprehensive clinical development programme leading to submission.
CRESTOR, ATACAND, ZESTRIL, TENORMIN, SELOKEN ZOK/TOPROL XL, PLENDIL, EXANTA
and GALIDA are Trade Marks of the AstraZeneca group of companies.
- Ends -
Item 3
ASTRAZENECA REPORTS SIGNIFICANT PROGRESS
ACROSS ITS PROMISING RESEARCH AND
DEVELOPMENT PORTFOLIO
AstraZeneca today updated analysts on the company's late stage development
products and projects; the progress of earlier stage products, notably in the
cardio-vascular and oncology therapeutic areas; and the improved productivity
in drug discovery, at its annual business review meeting in Alderley Park,
Cheshire, UK, a centre of excellence for Oncology Research and Development at
AstraZeneca.
Late Stage Development Progress and Product Line Extensions
o CRESTOR has received its first approval in The Netherlands, and will enter
European Mutual Recognition Procedure in December. The US NDA will be
supplemented with a data package in 1Q 2003; the Japan NDA was submitted
in 2Q 2002.
o EXANTA is set to be the first new oral anticoagulant for 50 years:
o The first indication in prevention of venous thromboembolism (VTE) in
patients undergoing orthopaedic surgery was filed in Europe in July
2002.
o Positive top-line results in the EXULT A study (confirming EXANTA's
efficacy in preventing VTE when compared to warfarin in US patients)
announced today will support the US filing for prevention of VTE in
orthopaedic surgery, scheduled for 4Q 2003.
o The main chronic indication, the prevention of stroke in patients
with atrial fibrillation, based on the SPORTIF trials, will be filed
in the US and Europe in 4Q 2003.
o Encouraging data from THRIVE III, the first study to report using
EXANTA in a chronic indication, were announced today and showed a
significant reduction in VTE events and no difference in bleeding
when compared to placebo. The study used a fixed dose of EXANTA
without the need for coagulation monitoring, which is normally
required for warfarin. A further indication for the treatment of VTE,
based on the THRIVE studies, will also be filed in Europe in 4Q 2003.
o Full details of EXULT A and THRIVE III will be presented at the
American Society of Hematology meeting in Philadelphia in December
2002.
o IRESSA, the first epidermal growth factor receptor inhibitor, is already
approved in Japan. In the US, IRESSA is under active review by the FDA,
following a positive US Oncology Drugs Advisory Committee (ODAC)
recommendation. A further ODAC meeting is not anticipated. The European
filing is now scheduled for 1Q 2003.
o The completion of the EU Mutual Recognition Procedure for approval of
ARIMIDEX in early breast cancer, a significant market opportunity, was
announced today. An approval has been granted in the UK and other European
approvals (Austria, Germany, Italy, Portugal and Spain) will follow.
ARIMIDEX was approved for early breast cancer in 3Q 2002 in the US, and
other reviews are ongoing in the rest of world.
o CASODEX is now approved for early prostate cancer (EPC) in 26 markets. An
EPC indication for CASODEX in the US will be the subject of a US ODAC
meeting scheduled for December 18th.
o FASLODEX has been approved for second-line treatment of breast cancer in
the US. European submission for this indication is scheduled for 2003,
while the Japanese submission is under consideration.
o NEXIUM is growing strongly with sales of $1.6 billion (MAT 3Q). New
indications for treatment of NSAID GI side effects and a new parenteral
formulation for the hospital setting will be submitted for approval in 2Q
2003.
o SEROQUEL, now a $1 billion brand, has demonstrated efficacy in treating
bipolar disease (mania). Filing for this indication is scheduled for 1Q
2003 in the US and Europe.
o Promising results for SYMBICORT in the treatment of chronic obstructive
pulmonary disease (COPD) (a $2.9 billion global market) were announced,
supporting the filing submitted to the EU earlier in 2002.
o Additional significant line extensions are planned for FASLODEX, IRESSA,
EXANTA, ATACAND, SEROQUEL and CRESTOR.
New Cancer Therapies
o Further information was provided on new cancer therapies that target
tumour growth mechanisms:
o ZD6474, an anti-angiogenic, in phase II development, and AZD2171,
another anti-angiogenic in phase I development, both target the
growth of blood vessels of tumours.
o ZD6126, a vascular targeting agent that will soon enter phase II
development, targets and destroys the vasculature of tumours, working
to destroy the tumour from within.
o AZD4054, an endothelin antagonist in phase II development, works by
inhibiting the ETA receptor, which is responsible for tumour cell
proliferation.
o AZD0530, an anti-invasive designed to prevent tumours from spreading,
will enter clinical testing in 2Q 2003.
o AZD3409, a prenylation inhibitor designed to inhibit proliferation of
cancer cells, will enter clinical testing in 2Q 2003.
New Cardiovascular Therapies
o Positive phase II data has been generated with GALIDA (AZ242), a new
treatment for type II diabetes.
o AZD6140, an anti-platelet approach to prevent blood clots (which can lead
to heart attacks and strokes) is currently in phase I development.
o AZD7009, a new treatment for atrial fibrillation, is also now in phase I
development.
New CNS/Pain Therapies
o Phase III clinical trials for NXY-059, a novel neuroprotectant for acute
stroke, will commence in early 2003.
o Encouraging clinical data was presented on AZD3582, the first Cox
Inhibiting Nitric Oxide Donator (CINOD) for pain control, further
demonstrating its attractive efficacy and side effect profile, versus
COX-2 selective NSAID's.
The full AstraZeneca development pipeline update is attached.
Drug Discovery Enhancements
o Candidate drug (CD) delivery has increased by 20 per cent in the last
three years--one quality CD is now entering preclinical development each
month.
o The number of CD's that have progressed to clinical development has
doubled this year.
o To increase the likelihood that CD's will progress through late-stage
development to market, AstraZeneca is:
o Bringing new aspects of clinical medicine to the drug discovery
process--enabling better understanding of human diseases and how
future drugs will work to prevent and treat those diseases.
o Front-loading risk in clinical development by introducing more
stringent safety and drug metabolism/pharmacokinetic (DMPK) testing
earlier--allowing for early identification of CD's that will not
succeed.
o 200 new collaborations with leading academic centres and biotech companies
have been initiated in 2002, supporting AstraZeneca's drug discovery
strategy.
Tom McKillop, Chief Executive, AstraZeneca, said:
"The transformation of AstraZeneca's product portfolio continues apace with
today's significant news of CRESTOR's first approval in Europe; progress with
other late stage development projects; and the announcement of a raft of
exciting new compounds in early development. A changing external environment
and the rapid adoption of new technologies are combining to provide new
challenges for the pharmaceutical industry, but they will also bring new
opportunities. We are driving productivity not only in R&D, but also in our
overall business--bringing forward new indications for our key growth products
and enhancing our sales forces effectiveness. By operating in a creative, fast
and efficient manner, I am confident that AstraZeneca will continue to deliver
important new medicines and deliver top-tier financial performance."
Jan Lundberg, Executive Vice President, Head of Global Discovery Research, in
an overview of the company's discovery strategy said:
"With the research environment increasingly focused on finding disease relevant
mechanisms combined with a plethora of fantastic new technologies, AstraZeneca
is working as one global team to improve the predictability of drug discovery.
We are introducing elements of clinical development in the earliest stages of
our activities to make our research as relevant to man as possible, and using
the latest technology for the early identification of projects unlikely to
succeed in development. These actions will result in a much better ratio of
CD's reaching the market. AstraZeneca has already been able to deliver a
fruitful pipeline that is admired across the industry, and we will continue to
populate that pipeline with novel quality compounds to provide added value and
benefits to patients worldwide, faster than ever before."
Martin Nicklasson, Executive Vice President, Head of Clinical Development, in
an overview of the AstraZeneca portfolio said:
"AstraZeneca's key growth products have delivered strong business performances
in the past year, and will continue to as their indications are broadened
through aggressive life-cycle management programmes. Underpinning an already
impressive portfolio of products in our key therapeutic areas, we are happy to
announce the progression of several promising early-stage research projects
including NXY-059, a novel neuroprotectant agent for stroke, GALIDA, a new
treatment for type II diabetes and lipid disorders, and our CINOD, AZD3582, a
new treatment for pain. These projects along with a score of others will ensure
the future success of AstraZeneca as a global leader in pharmaceutical research
and development."
7 November 2002
Media Enquiries: Steve Brown/Emily Denney (London) (020) 7304 5033/5034
Staffan Ternby (Sodertalje) (8) 553 26107
Rachel Bloom (Wilmington) (302) 886 7858
Analyst/Investor Enquiries: Mina Blair-Robinson (London) (020) 7304 5084
Jonathan Hunt (London) (020) 7304 5087
Staffan Ternby (Sodertalje) (8) 553 26107
Ed Seage (Wilmington) (302) 886 4065
Jorgen Winroth (New York) (212) 581 8720
For copies of the presentations from today's annual business review, please
visit www.astrazeneca.com.
This press release contains forward-looking statements with respect to
AstraZeneca's business. By their nature, forward-looking statements and
forecasts involve risks and uncertainties because they relate to events and
depend on circumstances that will occur in the future. There are a number of
factors that could cause actual results and developments to differ materially.
For a discussion of those risks and uncertainties, please see the company's
Annual Report/Form 20-F for 2001.
TRADE MARKS
The following brand names are trade marks of the AstraZeneca group of
companies:
ARIMIDEX, ATACAND, CASODEX, CRESTOR, EXANTA, FASLODEX, GALIDA,
IRESSA, NEXIUM, SYMBICORT, SEROQUEL.
AstraZeneca Development Pipeline: NCEs and line extensions
7 November 2002
Gastrointestinal
NCE's
-----------------------------------------------------------------------------------------------------------------------------------
Compound Mechanism Areas under Phase Estimated Filing
investigation ----------------------
MAA NDA
-----------------------------------------------------------------------------------------------------------------------------------
AZD0865 Reversible acid pump inhibitor Acid related GI disease I >2005 >2005
(was AR-H044277)
AZD3355 Inhibitor of transient lower Gastroesophageal reflux I >2005 >2005
esophageal sphincter disease (GERD)
relaxations (TLESR)
-----------------------------------------------------------------------------------------------------------------------------------
Line Extensions
-----------------------------------------------------------------------------------------------------------------------------------
Nexium(R) Proton pump inhibitor Treatment of NSAID GI III 2Q 2003 2Q 2003
Side effects
Nexium(R) Proton pump inhibitor Parenteral formulation III 2Q 2003 2Q 2003
Nexium(R) Proton pump inhibitor Prevention of NSAID GI III 1H 2004 1H 2004
Side effects
Nexium(R) Proton pump inhibitor Extraeosophageal reflux II >2005 >2005
disease
-----------------------------------------------------------------------------------------------------------------------------------
Cardiovascular
NCE's
-----------------------------------------------------------------------------------------------------------------------------------
Crestor(TM) Statin Hyperlipidemia III Filed Filed
Crestor(TM) Statin Atheroma III >2005 >2005
Crestor(TM) Statin Outcomes III >2005 >2005
Exanta(TM)(melagatran) Thrombin inhibitor (s.c) Prevention of VTE III Filed >2005
Exanta(TM)(H376/95) Thrombin inhibitor Prevention of VTE III Filed 4Q 2003
Exanta(TM)(H376/95) Thrombin inhibitor Prevention of stroke III 4Q 2003 4Q 2003
in AF
Exanta(TM)(H376/95) Thrombin inhibitor Treatment of VTE III 4Q 2003 >2005
Exanta(TM)(H376/95) Thrombin inhibitor Arterial/Post MI II >2005 >2005
AZ242 PPAR agonist Diabetes /Metabolic II >2005 >2005
Syndrome
AZD6140 ADP antagonist Arterial thrombosis I >2005 >2005
AZD7009 Atrial Repolarisation Delaying Atrial Fibrillation I >2005 >2005
Agent (ARDA)
AZD9684 CPU inhibitor Thrombosis PC >2005 >2005
AZD0837 Thrombin inhibitor Thrombosis PC >2005 >2005
AZD7806 IBAT inhibitor Dyslipidaemia PC >2005 >2005
-----------------------------------------------------------------------------------------------------------------------------------
Line Extensions
-----------------------------------------------------------------------------------------------------------------------------------
Atacand(R) Angiotensin II antagonist Hypertension outcomes III 4Q 2002* 4Q 2002*
(SCOPE)
Atacand(R) Angiotensin II antagonist CHF outcomes III 4Q 2003 4Q 2003
(CHARM)
Atacand(R) Angiotensin II antagonist Diabetic retinopathy III >2005 >2005
Toprol-XL(R) Beta-blocker HCTZ combination III >2005
-----------------------------------------------------------------------------------------------------------------------------------
*submission for variation to existing label.
CNS
NCE's
-----------------------------------------------------------------------------------------------------------------------------------
Compound Mechanism Areas under investigation Phase Estimated Filing
----------------------
MAA NDA
-----------------------------------------------------------------------------------------------------------------------------------
NXY-059 Free radical trapping agent Stroke III >2005 >2005
ZD 0947 K+ channel opener Overactive bladder II >2005 >2005
AR-A2 5HT1(beta) antagonist Anxiety/Depression I >2005 >2005
AZD1134 5HT1(beta) antagonist Anxiety/Depression PC >2005 >2005
AZD5106 NK-2 antagonist Overactive bladder PC >2005 >2005
AZD4750 Chemokine receptor antagonist Multiple sclerosis PC >2005 >2005
-----------------------------------------------------------------------------------------------------------------------------------
Line Extensions
-----------------------------------------------------------------------------------------------------------------------------------
Seroquel(R) D2/5HT2 antagonist Granules III 2004 2004
Seroquel(R) D2/5HT2 antagonist Sustained release III Under evaluation Under
evaluation
Seroquel(R) D2/5HT2 antagonist Mania III 1Q 2003 1Q 2003
Zomig(R) 5-HT1B/1D receptor agonist Nasal spray III Launched Filed
-----------------------------------------------------------------------------------------------------------------------------------
Oncology
NCE's
-----------------------------------------------------------------------------------------------------------------------------------
Faslodex(R) Oestrogen Receptor Antagonist 2nd line Advanced breast III 1Q 2003 Launched
cancer
Faslodex(R) Oestrogen Receptor Antagonist 1st line Advanced breast III >2005 >2005
cancer
Iressa(R) EGFR-TK inhibitor NSCLC III 1Q 2003 Filed
ZD6474 Angiogenesis inhibitor (Vascular Solid tumours II >2005 >2005
endothelial cell growth factor
receptor tyrosine kinase
inhibitor)
ZD4054 Endothelin A receptor antagonist Solid tumours II >2005 >2005
ZD6126 Vascular targeting agent Solid tumours I >2005 >2005
AZD2171 Angiogenesis inhibitor (Vascular Solid tumours and I >2005 >2005
endothelial cell growth factor haematological malignancies
receptor tyrosine kinase
inhibitor)
AZD3409 Farnesyl-transferase inhibitor Solid tumours PC >2005 >2005
( FAR )
AZD0530 Non-receptor tyrosine kinase Solid tumours PC >2005 >2005
inhibitor
AZD4440 Vascular targeting agent Solid tumours PC >2005 >2005
-----------------------------------------------------------------------------------------------------------------------------------
Line Extensions
-----------------------------------------------------------------------------------------------------------------------------------
Compound Mechanism Areas under investigation Phase Estimated Filing
-------------------------
MAA NDA
-----------------------------------------------------------------------------------------------------------------------------------
Arimidex(R) Aromatase inhibitor Adjuvant Breast Cancer III Approved Launched
Casodex(R) Anti-androgen Early Prostate Cancer III Launched Filed
Zoladex(R) LHRH agonist Pre-menopausal III Launched
Adjuvant Breast Cancer
Iressa(R) EGFR-TK inhibitor Head & Neck cancer III >2005 >2005
Iressa(R) EGFR-TK inhibitor Breast cancer II >2005 >2005
Iressa(R) EGFR-TK inhibitor Colorectal cancer II >2005 >2005
-----------------------------------------------------------------------------------------------------------------------------------
Respiratory and Inflammation
NCE's
-----------------------------------------------------------------------------------------------------------------------------------
AZD2315 Immuno modulator Rheumatoid Arthritis* II >2005 >2005
AZD4407 5-lipoxygenase inhibitor COPD I >2005 >2005
AZD9056 Ion channel blocker Rheumatoid Arthritis* I >2005 >2005
AZD8309 Chemokine receptor antagonist Rheumatoid Arthritis* PC >2005 >2005
AZD7140 Chemokine receptor antagonist Rheumatoid Arthritis* PC >2005 >2005
AZD3342 Protease Inhibitor COPD PC >2005 >2005
AZD0275 Chemokine receptor antagonist COPD PC >2005 >2005
AZD0902 Ion channel blocker COPD PC >2005 >2005
AZD8955 Collagenase inhibitor Osteoarthritis PC >2005 >2005
-----------------------------------------------------------------------------------------------------------------------------------
*First indication; use in other diseases eg. COPD under consideration.
Line Extensions
-----------------------------------------------------------------------------------------------------------------------------------
Symbicort(R)Turbuhaler(R) Inhaled steroid/fast onset, COPD III Filed
long-acting (beta)2 agonist
Symbicort(R)Turbuhaler(R) Inhaled steroid/fast onset, Single therapy for III 3Q 2003
long-acting (beta)2 agonist asthma
Symbicort(R)pMDI Inhaled steroid/fast onset, Asthma III 4Q 2003 1H 2004
long-acting (beta)2 agonist
Oxis(R)Turbuhaler(R) Long-acting (beta)2 agonist COPD III Filed
Oxis(R)pMDI Long-acting (beta)2 agonist Asthma III 3Q 2003
-----------------------------------------------------------------------------------------------------------------------------------
Pain Control
NCE's
-----------------------------------------------------------------------------------------------------------------------------------
Compound Mechanism Areas under Phase Estimated Filing
investigation ----------------------
MAA NDA
-----------------------------------------------------------------------------------------------------------------------------------
AZD3582 COX inhibiting nitric oxide Acute/chronic II >2005 >2005
donator nociceptive pain
AZD4282 NMDA Antagonist Neuropathic pain PC >2005 >2005
AZD 4717 COX inhibiting nitric oxide Acute/chronic PC >2005 >2005
donator nociceptive pain
-----------------------------------------------------------------------------------------------------------------------------------
Line Extensions
-----------------------------------------------------------------------------------------------------------------------------------
Naropin(R) Sodium channel blocker Spinal anaesthesia III Filed
-----------------------------------------------------------------------------------------------------------------------------------
Infection
Line Extensions
-----------------------------------------------------------------------------------------------------------------------------------
Merrem(R) Carbapenem antibiotic Skin and soft tissue III 4Q 2003
infections
-----------------------------------------------------------------------------------------------------------------------------------
AstraZeneca Development Pipeline: Discontinued Projects
GI
-----------------------------------------------------------------------
Compound Mechanism
-----------------------------------------------------------------------
Rofleponide Oral steroid
-----------------------------------------------------------------------
CV
-----------------------------------------------------------------------
Compound Mechanism
-----------------------------------------------------------------------
AZD7545 PDK Inhibitor
-----------------------------------------------------------------------
Respiratory and Inflammation
-----------------------------------------------------------------------
Compound Mechanism
-----------------------------------------------------------------------
Rofleponide palmitate Intranasal steroid
-----------------------------------------------------------------------
Infection
-----------------------------------------------------------------------
Compound Mechanism
-----------------------------------------------------------------------
Merrem(R)for use in neutropenics Carbapenem antibiotic
-----------------------------------------------------------------------
Comments
As disclosure of compound information is balanced by the business need to
maintain competitive advantage, some compound information has not been
disclosed at this time.
Compounds in development are displayed by phase.
Abbreviations:
PC - Pre-clinical: Candidate Drug accepted for development but not yet
administered to man.
MAA - Marketing Authorisation Application (Europe)
NDA - New Drug Application (USA)
7 November 2002
Item 4
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 8 November 2002, it purchased for
cancellation 15,000 ordinary shares of AstraZeneca PLC at a price of 2392 pence
per share. Upon the cancellation of these shares, the number of shares in issue
will be 1,725,357,312.
G H R Musker
Company Secretary
11 November 2002
Item 5
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 12 November 2002, it purchased for
cancellation 20,000 ordinary shares of AstraZeneca PLC at a price of 2462 pence
per share. Upon the cancellation of these shares, the number of shares in issue
will be 1,725,337,312.
G H R Musker
Company Secretary
13 November 2002
Item 6
ASTRAZENECA PLC - DIRECTORATE ANNOUNCEMENT
AstraZeneca PLC today announced that Ake Stavling will be leaving the Company
on 31 January 2003. Ake Stavling is 58 and has been an Executive Director since
April 1999. He played a key role in the integration of Astra and Zeneca
following the merger in 1999 and since then has been responsible for Business
Development. From 1993-1999 he was Executive Vice President and Chief Financial
Officer of Astra AB and before that held senior positions at Atlas Copco and
Ericsson.
G H R Musker
Company Secretary
14 November 2002
Item 7
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 13 November 2002, it purchased for
cancellation 650,000 ordinary shares of AstraZeneca PLC at a price of 2491
pence per share. Upon the cancellation of these shares, the number of shares in
issue will be 1,724,696,765.
G H R Musker
Company Secretary
14 November 2002
Item 8
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 14 November 2002, it purchased for
cancellation 300,000 ordinary shares of AstraZeneca PLC at a price of 2494
pence per share. Upon the cancellation of these shares, the number of shares in
issue will be 1,724,396,765.
G H R Musker
Company Secretary
15 November 2002
Item 9
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 15 November 2002, it purchased for
cancellation 250,000 ordinary shares of AstraZeneca PLC at a price of 2523
pence per share. Upon the cancellation of these shares, the number of shares in
issue will be 1,724,146,765.
G H R Musker
Company Secretary
18 November 2002
Item 10
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 20 November 2002, it purchased for
cancellation 500,000 ordinary shares of AstraZeneca PLC at a price of 2470
pence per share. Upon the cancellation of these shares, the number of shares in
issue will be 1,723,650,066.
G H R Musker
Company Secretary
21 November 2002
Item 11
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 21 November 2002, it purchased for
cancellation 300,000 ordinary shares of AstraZeneca PLC at a price of 2503
pence per share. Upon the cancellation of these shares, the number of shares in
issue will be 1,723,350,066.
G H R Musker
Company Secretary
22 November 2002
Item 12
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 22 November 2002, it purchased for
cancellation 430,000 ordinary shares of AstraZeneca PLC at a price of 2484
pence per share. Upon the cancellation of these shares, the number of shares in
issue will be 1,722,920,066.
G H R Musker
Company Secretary
25 November 2002
Item 13
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 25 November 2002, it purchased for
cancellation 500,000 ordinary shares of AstraZeneca PLC at a price of 2430
pence per share. Upon the cancellation of these shares, the number of shares in
issue will be 1,722,420,066.
G H R Musker
Company Secretary
26 November 2002
Item 14
DEALING BY DIRECTORS
COMPANIES ACT 1985 SECTION 324/329
WE HEREBY INFORM YOU THAT, ON 25 NOVEMBER 2002, WE WERE NOTIFIED BY DR H L
MOGREN, A DIRECTOR OF THE COMPANY, THAT, ON 25 NOVEMBER 2002, HE SOLD OPTIONS
OVER ASTRAZENECA PLC ORDINARY SHARES OF USD0.25 EACH AS FOLLOWS:-
NUMBER OF OPTIONS SOLD SALE PRICE PER DATE OF SALE
OPTION
9,217 67.59SEK 25.11.02
THESE OPTIONS WERE ORIGINALLY GRANTED TO DR MOGREN OVER SHARES IN ASTRA AB
UNDER THE ASTRA SHAREHOLDER VALUE INCENTIVE PLAN AND WERE CONVERTED INTO
OPTIONS OVER ORDINARY SHARES IN ASTRAZENECA PLC IN APRIL 1999. DETAILS OF THE
UNDERLYING ASTRAZENECA SHARES OVER WHICH THE OPTIONS WERE HELD ARE AS FOLLOWS:-
CLOSING PRICE OF
NUMBER OF ASTRAZENECA SHARES EFFECTIVE OPTION PRICE ASTRAZENECA SHARES ON
OVER WHICH OPTIONS WERE HELD PER SHARE DATE OPTIONS WERE SOLD
12,400 298.28SEK 345SEK
FOLLOWING THESE TRANSACTIONS, DR MOGREN HOLDS OPTIONS OVER 204,425 ORDINARY
SHARES OF ASTRAZENECA PLC.
G H R MUSKER
COMPANY SECRETARY
26 NOVEMBER 2002
Item 15
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 26 November 2002, it purchased for
cancellation 300,000 ordinary shares of AstraZeneca PLC at a price of 2435
pence per share. Upon the cancellation of these shares, the number of shares in
issue will be 1,722,120,066.
G H R Musker
Company Secretary
27 November 2002
Item 16
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 27 November 2002, it purchased for
cancellation 100,110 ordinary shares of AstraZeneca PLC at a price of 2445
pence per share. Upon the cancellation of these shares, the number of shares in
issue will be 1,722,763,772.
G H R Musker
Company Secretary
28 November 2002
Item 17
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announces that on 28 November 2002, it purchased for
cancellation 125,000 ordinary shares of AstraZeneca PLC at a price of 2461
pence per share. Upon the cancellation of these shares, the number of shares in
issue will be 1,722,638,772.
G H R Musker
Company Secretary
29 November 2002